D.H.E. 45 en es it fr

D.H.E. 45 Brand names, D.H.E. 45 Analogs

D.H.E. 45 Brand Names Mixture

  • No information avaliable

D.H.E. 45 Chemical_Formula

C33H37N5O5

D.H.E. 45 RX_link

http://www.rxlist.com/cgi/generic2/dihyergmes.htm

D.H.E. 45 fda sheet

D.H.E._45 FDA

D.H.E. 45 msds (material safety sheet)

D.H.E._45 MSDS

D.H.E. 45 Synthesis Reference

No information avaliable

D.H.E. 45 Molecular Weight

583.678 g/mol

D.H.E. 45 Melting Point

No information avaliable

D.H.E. 45 H2O Solubility

No information avaliable

D.H.E. 45 State

Solid

D.H.E. 45 LogP

No information avaliable

D.H.E. 45 Dosage Forms

Liquid

D.H.E. 45 Indication

For the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.

D.H.E. 45 Pharmacology

Dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT1Da and 5-HT1Db receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, noradrenaline a2A, a2B and a receptors, and dopamine D2L and D3 receptors. The therapeutic activity of Dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors.

D.H.E. 45 Absorption

Interpatient variable and may be dependent on the administration technique

D.H.E. 45 side effects and Toxicity

Side effects include abdominal pain, abnormal speech, coma, confusion, convulsions, hallucinations, increase and/or decrease in blood pressure, nausea, numbness, tingling, pain, and a bluish color of your fingersand toes, slowed breathing, vomiting

D.H.E. 45 Patient Information

PATIENT INFORMATIOn

Follow the link below to get detailed information before taking D.H.E. 45 (dihydroergotamine mesylate) Injection.

http://www.rxlist.com/cgi/generic2/dihyergmes_pi.htm

D.H.E. 45 Organisms Affected

Humans and other mammals